

**Table S5. Clinical variables and gastrointestinal toxicity.**

Characteristics	N	Gastrointestinal toxicity		$\chi^2$	p-value	OR	IC <sub>95%</sub>
		NO N (%)	YES (Grade 1-4) N (%)				
<b>Gender</b>	101						
Female	52	32(61.5)	20(38.5)	4.977	<b>0.026</b>	<b>2.78</b>	<b>1.14-7.20</b>
Male	49	40(81.6)	9(18.4)			<b>1</b>	-
<b>Age diagnosis PS</b>	101	29.1 (19.2-45.6)	23.8 (13.8-40.5)	-	0.247	-	-
<b>Family History of Ps</b>	101						
Yes	52	37 (71.2)	15 (28.8)	0.001	0.976	-	-
No	49	35 (71.4)	14 (28.6)				
<b>Smoking</b>	101						
Smoker	31	26 (83.9)	5 (16.1)	8.259	<b>0.016</b>	<b>1</b>	-
Non-smoking	49	36 (73.5)	13 (26.5)			<b>1.88</b>	<b>0.62-6.45</b>
Former Smoker	21	10 (47.6)	11 (52.4)			<b>5.72</b>	<b>1.66-22.34</b>
<b>Alcoholic drinking</b>	101						
Drinker	38	33 (86.8)	5 (13.2)	-	<b>0.013*</b>	<b>1</b>	-
Non-drinker	61	38 (62.3)	23 (37.7)			<b>3.99</b>	<b>1.46-12.96</b>
Former Drinker	2	1 (50.0)	1 (50.0)			<b>6.60</b>	<b>0.24-186.55</b>
<b>Type of Psoriasis</b>	101						
Plaque	74	57(77.0)	17(33.0)	-	0.105*	-	-
Pustular	5	2(40.0)	3(60.0)				
Inverse	1	1(100.0)	0(0.0)				
Guttate	5	2(40.0)	3(60.0)				
Plaque and guttate	12	6(50.0)	6(50.0)				
Plaque and inverse	2	2(100.0)	0(0.0)				
Plaque and pustular	1	1(100.0)	0(0.0)				
Plaque, guttate and inverse	1	1(100.0)	0(0.0)				
<b>Localization</b>							
<b>Trunk and limbs</b>	101						
Yes	93	65(69.9)	28(30.1)	-	0.433*	-	-
No	8	7(87.5)	1(12.5)				
<b>Scalp and face</b>	101						
Yes	77	53(68.8)	24(31.2)	0.955	0.329	-	-
No	24	19(79.2)	5(20.8)				
<b>Nails</b>	101						
Yes	58	37(63.8)	21(36.2)	3.738	<b>0.053</b>	<b>2.48</b>	<b>1.00-6.64</b>
No	43	35(81.4)	8(18.6)			<b>1</b>	-
<b>Palmoplantar</b>	101						
Yes	19	14(73.7)	5(26.3)	0.066	0.798	-	-
No	82	58(70.7)	24(29.3)				
<b>Flexures</b>	101						
Yes	28	23 (82.1)	5 (17.9)	2.230	0.135	-	-
No	73	49 (67.1)	24 (32.9)				
<b>Development of PSA</b>	101						
Yes	31	20(64.5)	11(35.5)	1.002	0.317	-	-
No	70	52(74.3)	18(25.7)				
<b>Comorbidities</b>	101						

Yes	57	41(71.9)	16(29.5)	0.026	0.871	-	-
No	44	31(70.5)	13(29.5)				
<b>Age of onset of MTX</b>	101	45.92±15.07	44.83±14.32	-	0.735	-	-
<b>MTX therapy duration (months)</b>	101	15.0 (5.8-29.5)	12.0 (5.0-38.0)	-	0.559	-	-
<b>MTX Administration</b>	101						
Oral	47	40 (85.1)	7 (14.9)	14.734	0.001	<b>1</b>	-
Subcutaneous	30	22 (73.3)	8 (26.7)			<b>2.08</b>	<b>0.66-6.68</b>
Both	24	10 (41.7)	14 (58.3)			<b>8.00</b>	<b>2.65-26.52</b>
<b>Type of MTX therapy</b>	101						
Monotherapy	93	66 (71.0)	27 (29.0)	0.059	0.809	-	-
Combination Therapy	8	6 (75.0)	2 (25.0)				
<b>Maximum MTX dose (mg/week)</b>	101	15.0 (10.0-15.0)	12.5 (10.0-15.0)	-	0.585	-	-
<b>Therapeutic adherence</b>	101						
Adherent	70	53 (75.7)	17 (24.3)	-	0.202*	-	-
Intentional non-adherent	30	18 (60.0)	12 (40.0)				
Unintentional non-adherent	1	1 (100.0)	0 (0.0)				

\*p-value for the Fisher's test. PS: psoriasis; PSA: psoriatic arthritis